The market growth is driven by key factors such as detection of genetic variation at high accuracy and drastic reduction in the cost of the test kits

Predictive genetic testing is generally a screening test taken by consumers to understand their likelihood of suffering with hereditary chronic diseases in later stages of their life.

Predispositional testing is spearheading the types segment on account of increasing number of women willing to undertake the predictive test to detect BRAC1 gene mutation and curb the prognosis of breast cancer in later stage of life. Presymptomatic test re becoming popular eventually due to its ability to accurately detect genetic mutations associated with chronic autoimmune diseases such as Huntington’s disease etc. it gives feasibility for family with family history of these disease to prepare accordingly to cope the socio-economic burden in later stage of the life.

The 35 -64 demographics held the largest market in 2018, which is 50.60% and will be the fastest growing segment as well during the forecast period. The major parameters responsible for its dominance are disposable income to undertake the predictive genetic testing and the most inquisitive population to understand the chances of occurrence of genetic disorders in the later stage of life. Age group of <35 is showcasing impressive growth owing to increasing health awareness pertaining to utilization of predictive genetic testing in curbing psycho-social effects pertaining to the chronic diseases in later part of life.

In 2018, North America held the largest market share of 38.69% in the regional segment for global predictive genetic testing market. The key parameters associated with the market dominance are increasing public health awareness regarding the utility of predictive testing in detecting potential gene mutations associated with chronic diseases which helps the consumer to plan his socioeconomic conditions to curb the severity of the disease in later part of life. Domicile of key players such as Agilent Technologies, Inc., 23andMe, Illumina, Inc., etc. further strengthens the market growth in the region. European Medical Agency (EMA) has laid stringent regulatory and ethical guidelines pertaining to the data sharing of consumers opting for predictive genetic testing. Effective collaboration between academic research institutes and major players I the development of predictive genetic testing kits. Asia Pacific is going to be the fastest growing regional segment in the near future on account of rising prevalence of genetic disorders and developing healthcare infrastructure.

The biopharmaceutical companies manufacturing predictive genetic testing kits are Agilent, Technologies, Inc., BGI Genomics, F.Hoffman-La Roche Ltd., Genes In Life., Invitae Corporation, Illumina, Inc., 23andMe, Myriad Genetics, Inc., Pathway Genomics and Thermo Fisher Scientific, Inc.

Key segments of the predictive genetic testing market

By Type, 2015-2025 (USD Million)

• Predispositional testing
• Presmptomatic testing

By Demographics, 2015-2025 (USD Million)

• <35
• 35 – 64
• 65+

Regional Overview, 2015-2025 (USD Million)

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Rest of MEA